Search

Comparative investigations were carried out on the absorption, antianemic action, and growth effect with newborn pigs with FB-82 and dextrofer-100 (an iron dextran complex with 100 mg Fe3+ per cm3) injected i/m. The FB-82 is a combined preparation of 3500000 IU Tylosine tartrate, 0.008 g cyanocobalamin, 0.5 g pyridoxine hydrochloride, 0.1 g tartaric acid, and iron dextran up to 100 cm3 (= 100 mg Fe3+/cm3). Dextrofer-100 enriched with 50 mg Zn, 0.5 mg Co, 200 micrograms cyanocobalamin, and 100 mg pyridoxine hydrochloride for 100 cm3 under the compound name of fericin was also used to compare the anti-anemic effect of FB-82 and dextrofer-100. It was found that FB-82 applied to newborn pigs in a single dose of 2 cm3, i/m, was well absorbed; it developed high concentrations of tylosine in the plasma, and its sideremia and antianemic action were similar to those induced by an equivalent (with regard to iron) amount of dextrofer-100, whereas the result concerning the hematocrit value was better. Compared to dextrofer-100 the FB-82 preparation have better protection to pigs (lowered the mortality rate) and induced better development of the animals. Fericin did not differ essentially from FB-82 in terms of its effect on the red blood picture, however, the percent of protected pigs was lower.

Studies are the following preparations, produced by "PHARMACHIM": tylosine-base (Tylosine-50), tylosine tartarate (Tylosine pulvis) and tylosine phosphate (substance and granules) and their analogues: tylosine-base (Tylan-50), tylosine tartarate (Tylan soluble) and tylosine phosphate (Tylan AF 99), produced by the "Elanco" Company. The biological activity of the preparation was determined by means of the microbiological method of diffusion in agar. In the case of all experimental treatments, the preparations were compared in conformity with their biological activity expressed in IU/mg of the preparations. The minimum inhibition concentrations of the preparations were determined by the method of serial dilutions in liquid nutritive media on 19 different pathogenic strains. The antispirochetal activity of the preparations compared was tested on 130 cockerels and pullets, experimentally infected with Borrelia anserina of the Surnevo and Pamoukchii serotypes. The application of the preparations started simultaneously with the infection or 24 and 48 hrs after it and continued for days. No significant differences are found in the antibacterial and antispirochetal activities of the Bulgarian tylosine preparations and those manufactured by the "Elanko" Company. The tylosine base does not differ significantly in its antimicrobial and antispirochetal activities from the tylosine phosphate and the tylosine tartarate when equal in IU concentrations and doses are applied.

A pharmacologic evaluation was made of a technologic model of a liquid drug form (code name phi B-82), having the following composition: tylosine tartrate 3500000 UI, cyanocobalamine 0.008 g, pyridoxin hydrochloride 0.500 g, tartaric acid 0.100 g, and feridextran (dextrofer-100) up to 100 cm3; pH from 5.5 to 6.5, and Fe3+ 100 mg/cm3. It was found that phi B-82 at i/m application to rabbits, subcutaneous injection to albino mice, and intra-abdominal introduction to albino rats and mice at rates that were equal to ED100 and 3 to 5 times higher than those used with pigs did not lead to local and total lack of tolerance. The acute toxicity (LD50) of phi B-82 at intra-abdominal application to 18-20 g albino mice was 29.2 cm3/kg. The single muscular application to guinea pigs at 2 cm3 per kg of body mass showed good absorption of the preparation - it did not differ essentially from those of dextrofer-100 and aquaous solution of tylosine tartrate used in equivalent amounts. The bacteriostatic concentrations of tylosine were maintained for 24 hours. It was shown that the optimal effect would be produced by a combined preparation having the qualities of the feridextrane complexes with a rapid absorption and those of the erythropoietic vitamins of the B12 group and B6 along with the participation of tylosine as an antibiotic.